XML 69 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Note 11 - Related Party Transactions (Details Textual)
3 Months Ended 12 Months Ended
Jan. 09, 2024
USD ($)
May 04, 2023
USD ($)
Mar. 31, 2024
USD ($)
shares
Dec. 31, 2023
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Aug. 01, 2019
USD ($)
ft²
Feb. 28, 2018
USD ($)
Operating Expenses     $ 245,158,000   $ 268,171,000      
Area of Real Estate Property (Square Foot) | ft²             29,500  
Operating Leases, Monthly Payments, Year One             $ 89,000  
Operating Leases, Monthly Payments, Year Five             $ 101,000  
Beckman Coulter [Member]                
Related Party Transaction, Amounts of Transaction     600,000          
Integrated DNA Technologies Inc. [Member]                
Related Party Transaction, Amounts of Transaction     1,000,000          
Leica Microsystems Inc. [Member]                
Related Party Transaction, Amounts of Transaction     100,000          
Transition Services Agreement [Member] | GeneDx [Member]                
Operating Expenses     1,200,000          
Accounts Receivable, after Allowance for Credit Loss     0          
Transition Services Agreement [Member] | GeneDx [Member] | Services Rendered [Member]                
Operating Expenses     0          
Reimbursement of Travel Expenses [Member] | Executive Officer [Member]                
Related Party Transaction, Amounts of Transaction     $ 0   $ 29,300      
Ruen-Hui Biopharmaceuticals, Inc. [Member]                
Equity Method Investment, Ownership Percentage   10.00%            
Ruen-Hui Biopharmaceuticals, Inc. [Member] | License Agreement [Member]                
Payments to Acquire Equity Method Investments   $ 150,000            
Collaborative Arrangement, Maximum Regulatory Milestone Payments   $ 1,000,000            
Pharmsynthez [Member]                
Equity Method Investment, Ownership Percentage     9.00%          
Pharmsynthez [Member] | Director [Member]                
Investment Owned, Balance, Shares (in shares) | shares     3          
Zebra [Member]                
Equity Method Investment, Ownership Percentage     29.00%          
ChromaDex Corporation [Member]                
Equity Method Investment, Ownership Percentage     0.05%          
COCP [Member]                
Equity Method Investment, Ownership Percentage     2.00%          
NIMS [Member]                
Equity Method Investment, Ownership Percentage     1.00%          
Eloxx Pharmaceuticals, Inc. [Member]                
Equity Method Investment, Ownership Percentage     1.00%          
BioCardia [Member]                
Equity Method Investment, Ownership Percentage     1.00%          
LeaderMed [Member]                
Equity Method Investment, Ownership Percentage     47.00%          
Neovasc [Member]                
Equity Method Investment, Ownership Percentage     0.50%          
Proceeds from Sale of Equity Method Investments       $ 363,000   $ 363,000    
GeneDx [Member]                
Equity Method Investment, Ownership Percentage     13.70%          
InCellDx [Member]                
Equity Method Investment, Ownership Percentage       29.00%   29.00%    
The 2029 Convertible Notes [Member]                
Debt Instrument, Face Amount $ 230,000,000              
The 2029 Convertible Notes [Member] | Convertible Debt [Member]                
Debt Instrument, Issued, Principal 71,100,000              
The 2023 Convertible Notes [Member]                
Interest Payable 16,100,000              
The 2023 Convertible Notes [Member] | Convertible Debt [Member]                
Debt Instrument, Face Amount 55,000,000             $ 55,000,000
Interest Payable $ 16,100,000